Janssen Pharmaceutica N.V., Belgium

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Janssen Pharmaceutica N.V., Belgium sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Janssen Pharmaceutica N.V., Belgium: 6 sponsored US clinical trials, none currently recruiting.

Janssen Pharmaceutica N.V., Belgium sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Critical Confirmed Coronavirus Disease (COVID)-19, with 1 trials.

Upper-quartile sponsor footprint

Janssen Pharmaceutica N.V., Belgium sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616
ACTIVE NOT RECRUITING Phase 3

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059
COMPLETED Phase 2

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

NCT05328297
COMPLETED Phase 2

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961
COMPLETED Phase 1

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

NCT04006704
COMPLETED

Idylla IFV-RSV Panel Clinical Testing

NCT02786381

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 1

Therapeutic Areas

Critical Confirmed Coronavirus Disease (COVID)-19 1
Preclinical Alzheimer's Disease 1
Prostatic Neoplasms 1
HIV-1 1

How the Janssen Pharmaceutica N.V., Belgium early-phase archive is shaped

6 indexed studies, none listed as recruiting (0% open); 4 completed (67%).

Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Critical Confirmed Coronavirus Disease (COVID)-19 (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Janssen Pharmaceutica N.V., Belgium: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Janssen Pharmaceutica N.V., Belgium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Janssen Pharmaceutica N.V., Belgium23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Janssen Pharmaceutica N.V., Belgium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Janssen Pharmaceutica N.V., Belgium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Janssen Pharmaceutica N.V., Belgium page

6 registered trials is a research-attention snapshot, not an endorsement of Janssen Pharmaceutica N.V., Belgium or any single study.

  • None of Janssen Pharmaceutica N.V., Belgium's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Critical Confirmed Coronavirus Disease (COVID)-19 is the condition Janssen Pharmaceutica N.V., Belgium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Critical Confirmed Coronavirus Disease (COVID)-19 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Janssen Pharmaceutica N.V., Belgium pipeline card: 6 registered trials from official public datasets.Report a data error.